Seattle Genetics, Inc. has recieved a license fee in an undisclosed amount from Genencor International, Inc. under the terms of a strategic alliance formed by the two companies in January 2002. The collaboration involves the joint discovery and development of a class of cancer therapeutics based on tumor-targeted enzymes that activate prodrugs. At the time Read more about Seattle Genetics Receives License Fee From Genencor[…]
Epimmune Inc. has entered into an evaluation and license option agreement with Immuno-Designed Molecules, S.A. (IDM) for certain cancer antigens for use in IDM’s ex vivo cancer therapy program. Under the terms of the agreement, IDM will have 120 days from the date of the option agreement to evaluate the epitopes and exercise its option Read more about Epimmune And Immuno-designed Molecules Agree License Option[…]
Inex Pharmaceuticals Corporation has formed a joint venture with Elan Corporation, plc for the development and commercialisation of INEX’s lead product, Onco TCS, now being evaluated in human clinical trials as a treatment for a number of cancers. INEX and Elan have both contributed assets to the joint venture including worldwide rights to Onco TCS Read more about Inex Forms Joint Venture With Elan[…]
Panacea Pharmaceuticals, Inc. has signed a Collaborative Research Agreement with researchers at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts covering the development of all-human, ultra-affinity, single-chain antibodies for its cancer platform technology. The research group is led by K. Dane Wittrup, Ph.D., J.R. Mares Professor of Chemical Engineering and Bioengineering at MIT. Dr. Read more about Panacea Announces Collaboration With MIT[…]
Schering AG and MediGene AG has announced the formation of a world-wide strategic alliance to develop and commercialise MediGene’s Viral Vaccine for the treatment of precancerous lesions of the cervix caused by human papilloma viruses (HPV). Schering has been granted a world-wide exclusive license with the right to grant sublicenses. MediGene has an option for Read more about Schering And MediGene Collaborate On Human Papilloma Virus Treatment[…]
Xenerex Biosciences, a subsidiary of AVANIR Pharmaceuticals, and Peregrine Pharmaceuticals, Inc. have announced that they have entered into an antibody research collaboration agreement, designed to discover, develop and potentially commercialise fully human monoclonal antibody therapies for the treatment of solid tumour cancers. “Our opportunity to work with Peregrine is yet another step forward in validating Read more about Xenerex And Peregrine Announce Research Collaboration[…]